Related Experiment Video
Updated: May 7, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Hepatic xanthoma associated with pasireotide administration: a first case report
Fan-Chun Meng1, Tai-Kuang Chao, Hsin-Hung Huang
1Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taiwan.
Internal Medicine (Tokyo, Japan)
|October 4, 2013
Summary
This is the first reported case of hepatic xanthoma caused by the drug pasireotide. The liver lesion significantly decreased in size after discontinuing the medication, suggesting pasireotide as the likely cause.
Area of Science:
- Hepatology
- Oncology
- Pharmacology
Background:
- Hepatic xanthoma is an exceptionally rare liver lesion.
- Pasireotide is a somatostatin analog used in clinical trials.
Observation:
- A 27-year-old Taiwanese male developed hepatic xanthoma during a pasireotide clinical trial.
- This represents the first documented instance of pasireotide-induced hepatic xanthoma.
Findings:
- The hepatic xanthoma showed a 98.2% reduction in tumor volume after pasireotide discontinuation.
- The tumor regression suggests a direct link between pasireotide and hepatic xanthoma development.
Implications:
- Periodic liver radiological examinations are recommended for patients on pasireotide, regardless of risk factors.
- Observation and potential drug withdrawal may be sufficient management, avoiding immediate medical or surgical intervention.
